Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone. It serves employers, health plans, health systems, and other entities in approximately 100 countries worldwide.
Read More…
Industry, Sector and Symbol
Industry Offices & clinics of medical doctors
Sub-IndustryN/A
SectorMedical
Phone203-635-2002
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$417.91 million
Profitability
Miscellaneous
Employees2,000
Next Earnings Date2/26/2020 (Confirmed)
OptionableOptionable
Teladoc Health (NYSE:TDOC) Frequently Asked Questions
What is Teladoc Health's stock symbol?
Teladoc Health trades on the New York Stock Exchange (NYSE) under the ticker symbol "TDOC."
How were Teladoc Health's earnings last quarter?
Teladoc Health Inc (NYSE:TDOC) posted its quarterly earnings data on Wednesday, October, 30th. The health services provider reported ($0.28) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.40) by $0.12. The health services provider earned $137.96 million during the quarter, compared to analysts' expectations of $136.46 million. Teladoc Health had a negative return on equity of 11.23% and a negative net margin of 20.15%. The business's quarterly revenue was up 24.3% on a year-over-year basis. During the same quarter last year, the firm earned ($0.34) EPS. View Teladoc Health's Earnings History.
When is Teladoc Health's next earnings date?
How can I listen to Teladoc Health's earnings call?
Teladoc Health will be holding an earnings conference call on Wednesday, February 26th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.
What guidance has Teladoc Health issued on next quarter's earnings?
Teladoc Health updated its fourth quarter 2019
Pre-Market earnings guidance on Monday, January, 13th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $155-156 million, compared to the consensus revenue estimate of $151.68 million.
What price target have analysts set for TDOC?
20 brokerages have issued 1-year target prices for Teladoc Health's stock. Their forecasts range from $70.00 to $116.00. On average, they anticipate Teladoc Health's share price to reach $94.25 in the next year. This suggests that the stock has a possible downside of 15.7%. View Analyst Price Targets for Teladoc Health.
What is the consensus analysts' recommendation for Teladoc Health?
20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teladoc Health in the last year. There are currently 8 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Teladoc Health.
What are Wall Street analysts saying about Teladoc Health stock?
Here are some recent quotes from research analysts about Teladoc Health stock:
- 1. According to Zacks Investment Research, "Teladoc Health’s shares have outperformed the industry year to date. With a number of acquisitions completed since its inception, the company has expanded its distribution capabilities and broadened its service offering. The company has started international expansion with the acquisition of Advance Medical in 2018, which was built on its buyout of Best Doctors in 2017. In 2018, the company launched Global Care Services which caters to its international business. It has been witnessing continued growth in revenues over the quarters, driven by an increase in membership and patient visits. However, the company has incurred significant loss and has been unable to generate cash from operations. Its struggle may continue in the coming quarters. Its high debt level and interest expense weigh on margins." (11/27/2019)
- 2. Cantor Fitzgerald analysts commented, ". We reiterate our Neutral rating on TDOC shares. Our price target is $70. After the close on Tuesday, April 30, TDOC reported 1Q18 results that were in line with our estimates and reaffirmed its 2019 guidance. Organic revenue growth was 23% compared with 31% in 4Q18. Importantly, the company indicated that it has expanded its relationship with UnitedHealthcare (UNH – Overweight). The company reiterated that it should be able to maintain organic revenue growth in the 20-30% range next year. The company remains optimistic on Medicare Advantage (MA) plans, but expects more ratable adoption over time. On the surface, TDOC is executing nicely on its virtual health strategy." (4/30/2019)
Has Teladoc Health been receiving favorable news coverage?
Media coverage about TDOC stock has been trending very negative on Tuesday, according to InfoTrie Sentiment Analysis. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Teladoc Health earned a news impact score of -3.0 on InfoTrie's scale. They also gave media coverage about the health services provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Teladoc Health.
Who are some of Teladoc Health's key competitors?
Some companies that are related to Teladoc Health include LONZA GRP AG/ADR (LZAGY), Takeda Pharmaceutical (TKPYY), Actelion (ALIOF), COLOPLAST A/S/ADR (CLPBY), McKesson (MCK), FRESENIUS SE &/S (FSNUY), TERUMO CORP/ADR (TRUMY), Centene (CNC), DexCom (DXCM), ResMed (RMD), OLYMPUS CORP/S (OCPNY), IDEXX Laboratories (IDXX), Fresenius Medical Care AG & Co. (FMS), Cerner (CERN) and Eisai (ESALY).
What other stocks do shareholders of Teladoc Health own?
Who are Teladoc Health's key executives?
Teladoc Health's management team includes the folowing people:
- Mr. Jason Nathanial Gorevic, CEO & Director (Age 47)
- Mr. Peter A. McClennen, Pres & Interim COO (Age 50)
- Mr. Adam Christian Vandervoort, Chief Legal Officer & Sec. (Age 44)
- Ms. Stephany Verstraete, Chief Marketing Officer (Age 50)
- Dr. George Byron Brooks BS EE, M.D., Co-Founder
When did Teladoc Health IPO?
(TDOC) raised $112 million in an initial public offering (IPO) on Wednesday, July 1st 2015. The company issued 7,000,000 shares at $15.00-$17.00 per share. J.P. Morgan and Deutsche Bank Securities served as the underwriters for the IPO and William Blair, Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.
Who are Teladoc Health's major shareholders?
Teladoc Health's stock is owned by many different of institutional and retail investors. Top institutional investors include Baillie Gifford & Co. (7.92%), Zevenbergen Capital Investments LLC (2.21%), State Street Corp (2.04%), Riverbridge Partners LLC (2.00%), Champlain Investment Partners LLC (1.74%) and Sumitomo Mitsui Trust Holdings Inc. (1.27%). Company insiders that own Teladoc Health stock include Adam C Vandervoort, Andrew Turitz, Gabriel R Cappucci, Jason N Gorevic, Lewis Levy, Mark Hirschhorn, Michael Goldstein, Michelle Bucaria, Peter A Mcclennen and Stephany Verstraete. View Institutional Ownership Trends for Teladoc Health.
Which institutional investors are selling Teladoc Health stock?
TDOC stock was sold by a variety of institutional investors in the last quarter, including Symphony Asset Management LLC, Zevenbergen Capital Investments LLC, Artisan Partners Limited Partnership, Riverbridge Partners LLC, Eagle Asset Management Inc., Jennison Associates LLC, Sectoral Asset Management Inc and ARK Investment Management LLC. Company insiders that have sold Teladoc Health company stock in the last year include Adam C Vandervoort, Andrew Turitz, Gabriel R Cappucci, Jason N Gorevic, Lewis Levy, Michael Goldstein, Michelle Bucaria and Peter A Mcclennen. View Insider Buying and Selling for Teladoc Health.
Which institutional investors are buying Teladoc Health stock?
TDOC stock was purchased by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Renaissance Technologies LLC, Point72 Asset Management L.P., Goldman Sachs Group Inc., Mitsubishi UFJ Trust & Banking Corp, Toronto Dominion Bank, Champlain Investment Partners LLC and Blair William & Co. IL. View Insider Buying and Selling for Teladoc Health.
How do I buy shares of Teladoc Health?
Shares of TDOC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Teladoc Health's stock price today?
One share of TDOC stock can currently be purchased for approximately $111.77.
How big of a company is Teladoc Health?
Teladoc Health has a market capitalization of $8.09 billion and generates $417.91 million in revenue each year. The health services provider earns $-97,080,000.00 in net income (profit) each year or ($1.44) on an earnings per share basis. Teladoc Health employs 2,000 workers across the globe.View Additional Information About Teladoc Health.
What is Teladoc Health's official website?
How can I contact Teladoc Health?
Teladoc Health's mailing address is 2 MANHATTANVILLE ROAD SUITE 203, PURCHASE NY, 10577. The health services provider can be reached via phone at 203-635-2002 or via email at [email protected]
MarketBeat Community Rating for Teladoc Health (NYSE TDOC)
MarketBeat's community ratings are surveys of what our community members think about Teladoc Health and other stocks. Vote "Outperform" if you believe TDOC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TDOC will underperform the S&P 500 over the long term. You may vote once every thirty days.
